Treffer: Decentralized biobanking platform for organoid research networks.

Introduction: Organoids are living, patient-derived tumor models that are revolutionizing precision medicine and drug development, however current privacy practices strip identifiers, thereby undermining ethics, efficiency, and effectiveness for patients and research enterprises alike. Decentralized biobanking "de-bi" applies non-fungible tokens (NFTs) to empower privacy-preserving specimen tracking and data sharing for networks of scientists, donors, and physicians. We design, develop, and demonstrate a functional de-bi platform for a real-world organoid biobank. Methods: Ethnography of the organoid biobanking ecosystem was performed in 2022–2023, with site visits, interviews, focus groups, and structured observations of stakeholder interactions. An initial ERC-721 prototype was developed and tested, informing the design of a comprehensive NFT model. Web and mobile app prototypes were developed with a suite of ERC-1155 protocols representing ecosystem constituents as NFTs. We demonstrated the platform with publicly available Human Cancer Models Initiatives organoids to establish proof-of-concept for decentralized biobanking as the foundation of a democratized biomedical metaverse, or "biomediverse." Results: Scientists revealed key challenges for organoid research and development under policy, scientific, and economic constraints of the life science landscape. We advanced decentralized biobanking as a blockchain overlay network solution with potential to overcome barriers, enhance utility and unlock value by uniting collaborators in a privacy-preserving biomediverse. Dedicated smart contracts created "soulbound" NFTs as de-identified digital twins of patients, physicians, and scientists in a networked organoid ecosystem. We modeled biospecimen collection, processing, and distribution, including generation and expansion of organoids, via an auditable on-chain mechanism. Key features included the ability to bootstrap the digital twin NFT model onto an established organoid biobank, visibility of patient-linked biospecimens and related research activities for all ecosystem participants, as well as tooling for multisided data exchange. Implementing de-bi with ERC-1155 showed potential to minimize gas costs of on-chain activity vs ERC-721, though complementary layer-2 solutions will be essential for economic viability. Conclusion: Decentralized biobanking has the potential to enhance efficiency, increase translational impact and drive research discovery through implementation of NFT digital twins for organoid research networks. Importantly, this approach also bolsters ethical practices by fostering inclusion, ensuring transparency, and enhancing accountability across the research ecosystem. Next steps include live pilot testing, market design research to align stakeholder incentives, and technical solutions to support a sustainable, scalable and mutually rewarding biomediverse. [ABSTRACT FROM AUTHOR]

Copyright of Frontiers in Blockchain is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)